{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-266860","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.250065+00:00","generated_at":"2026-05-17T00:20:20.173202+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Adicet Bio Q3 net loss $26.9M; positive ADI-001 Phase 1 data in LN/SLE; cash runway extended to H2 2027","bullets":["Positive Phase 1 ADI-001 data in 7 LN/SLE patients: SLEDAI-2K reductions, improved renal function, no Grade 2+ CRS or ICANS.","Plans FDA meeting Q1 2026 for potentially pivotal trial; initiation targeted Q2 2026.","Q3 2025 net loss $26.9M ($0.29 loss per share); R&D $22.9M, G&A $5.1M; cash $103.1M as of Sep 30.","Raised $74.8M net proceeds in October 2025 registered direct offering; cash runway into H2 2027.","ADI-212 regulatory filing for mCRPC on track Q1 2026; initial data expected H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-266860","json":"https://secwatch.observer/filing/0001193125-25-266860.json","markdown":"https://secwatch.observer/filing/0001193125-25-266860.md","text":"https://secwatch.observer/filing/0001193125-25-266860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525266860/0001193125-25-266860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525266860/acet-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:20:20.173202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}